Compare CYCU & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYCU | GDTC |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 10.4M |
| IPO Year | 2021 | 2021 |
| Metric | CYCU | GDTC |
|---|---|---|
| Price | $3.81 | $0.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 24.1K |
| Earning Date | 06-05-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,771,485.00 | N/A |
| Revenue This Year | $8.92 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.68 |
| 52 Week High | $7.13 | $3.68 |
| Indicator | CYCU | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 86.39 | 51.28 |
| Support Level | $0.69 | $0.93 |
| Resistance Level | $4.46 | $1.09 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 91.05 | 63.33 |
Cycurion Inc. provides information technology security solutions through its subsidiaries. The company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company has one reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.